Lebwohl David
EVP, Chief Medical Officer
Lebwohl David has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Mar 3, 2026.
On the most recent filing, Lebwohl David is listed as EVP, Chief Medical Officer at Intellia Therapeutics, Inc. Inside the rolling window, Lebwohl David reported no open-market purchases and 1 open-market sale totaling $110K in NTLA.
Companies traded
Other insiders at NTLA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$110K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Lebwohl David made?
Lebwohl David has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Lebwohl David trade?
Lebwohl David has filed SEC Form 4 disclosures for 1 company, including NTLA.
When was Lebwohl David's most recent SEC Form 4 filing?
Lebwohl David's most recent SEC Form 4 filing on Tracefour is dated Mar 3, 2026.
What is Lebwohl David's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Lebwohl David is listed as EVP, Chief Medical Officer.
What is Lebwohl David's total buy and sell value in the current window?
Inside the rolling retention window, Lebwohl David bought $0 and sold $110K based on SEC Form 4 filings.
What was Lebwohl David's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 11,903 NTLA shares on 2026-01-05, worth $110K, per SEC Form 4 filings.